Back to results
US 2020/0345845 A1Published application
Compositions and methods related to cell systems for penetrating solid tumors
AssigneeRubius Therapeutics, Inc.
InventorsAvak Kahvejian, Robert J. Deans, Jordi Mata-Fink, Sivan Elloul, Nathan Dowden
Life of this patent
Estimating the term…
Abstract
The present disclosure provides, e.g., compositions and method for treating cancers, e.g., solid tumors. In embodiments, the compositions comprise an erythroid cell expressing an exogenous polypeptide, e.g., a polypeptide that promotes penetration of the erythroid cell into the solid tumor.
Claims20
A method of delivering a binding agent to an extravascular site in a subject comprising:
- administering to the subject's bloodstream an effective amount of a preparation comprising a plurality of enucleated erythroid cells, wherein an enucleated erythroid cell of the plurality of enucleated erythroid cells comprises, on its surface, an exogenous polypeptide comprising a binding agent, wherein the binding agent comprises an antibody, an antibody fragment, a single-chain antibody, an scFv, or a nanobody;
- against an antigen present at an extravascular site,
- thereby delivering the binding agent to the extravascular site.
A method of treating a subject having a resistant cancer comprising:
- administering to the subject's bloodstream a preparation comprising a plurality of enucleated erythroid cells, wherein an enucleated erythroid cell of the plurality of enucleated erythroid cells comprises, on its surface, an exogenous polypeptide comprising a binding agent, wherein the binding agent comprises an antibody, an antibody fragment, a single-chain antibody, an scFv, or a nanobody against a tumor cell antigen, in an amount sufficient to treat the resistant cancer,
- thereby treating the resistant cancer.
A method of treating a vascularized solid tumor in a subject comprising:
- administering to the subject's bloodstream a preparation comprising a plurality of enucleated erythroid cells, wherein an enucleated erythroid cell of the plurality of enucleated erythroid cells comprises, on its surface, an exogenous polypeptide comprising a binding agent, wherein the binding agent comprises an antibody, an antibody fragment, a single-chain antibody, an scFv, or a nanobody against a tumor cell antigen, in an amount sufficient to treat the vascularized solid tumor, thereby treating the vascularized solid tumor.
Dependencies are inferred from the claim text.